A Review on Theranostics: An Approach to Targeted Diagnosis and Therapy

Authors

  • Saumya Shrivastava Department of Pharmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India
  • Saloni Jain Department of Pharmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India
  • Deepak Kumar Department of Pharmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India
  • Shankar Lal Soni Department of Parmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India
  • Mukesh Sharma Department of Parmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

DOI:

https://doi.org/10.22270/ajprd.v7i2.463

Keywords:

Diagnosis, therapy, theranostics, nuclear medicine, nanomedicine

Abstract

Emerging as a targeted, safe, and efficient pharmacotherapy is the approach of theranostics, which focuses on patient centered care. It is a combination of diagnosis and therapeutics. Theranostics is a new field of medicine which combines specific targeted therapy based on specific targeted diagnostic tests. With a key focus on patient centered care, theranostics provides a transition from conventional medicine to a contemporary personalized and precision medicine approach. The theranostics paradigm involves using nanoscience to unite diagnostic and therapeutic applications to form a single agent, allowing for diagnosis, drug delivery and treatment response monitoring. The theranostics medicine can achieve systemic circulation, evade host defenses and deliver the drug and diagnostic agents at the targeted site to diagnose and treat the disease at cellular and molecular level.

 

 

Downloads

Download data is not yet available.

Author Biographies

Saumya Shrivastava, Department of Pharmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

Department of Pharmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

Saloni Jain, Department of Pharmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

Department of Pharmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

Deepak Kumar, Department of Pharmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

Department of Pharmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

Shankar Lal Soni, Department of Parmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

Department of Parmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

Mukesh Sharma, Department of Parmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

Department of Parmaceutics, Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India

References

1. Thangadurai M, Nalliapan G, Janardhanam DS, et al. Theranostics an Emerging Paradigm- a Review. IOSR Journal of Dental and Medical Sciences. 2018; 17(11): 01-07.
2. Jeelani S, Reddy RC, Maheswaran T, Asokan GS, Dany A, Anand B. Theranostics: A treasured tailor for tomorrow, J Pharm Bioallied Sci. 2014 ;6(1):S6-8.
3. Madaswamy S. Muthu, David Tai Leong, Lin Mei, Si-Shen Feng. Nanotheranostics ˗ Application and Further Development ofNanomedicine Strategies for Advanced Theranostics, Theranostics 2014; 4(6):660-677.
4. Ken Herrmann, Steven M. Larson and Wolfgang A. Weber. TheranosticConcepts: More Than Justa Fashion Trend—Introduction andOverview. J Nucl Med, 2017; 58(2).
5. Anna Y, Elisabeth E, Stefan K, Ralph AB, Stefan S, Maria GC, Georg F, Hojjat A, Markus E. Theranostics in nuclear medicine practice. OncoTargets and Therapy: Dovepress, 2017;10
6. Warland S, Hesse M, Renauld L, Jumar F. The impact of image reconstruction bias on PET/CT90 Y dosimetry after radioemobilisation. J Nucl Med, 2015; 56(3):494-495.
7. LusterM, Clarke S.E, Dietlein M, Lassmann M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008; 35(10):1941-1949.
8. Sonali, Viswanadh MK, Singh RP, Agrawal P, Mehata AK, Pawde DM, Narendra , Sonkar R, Muthu MS. Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer. Nanotheranostics 2018; 2(1):70-86.
9. Shapiro A, Livney YD, broxterman HJ, Assaraf YG. Nanomedicine for Targeted Cancer Therapy: towards the overcoming of drug resistance. Drug Resist Update 2011; 14(3):150-163.
10. mmy D.G. Fleuren, Yvonne M.H., Versleijen-Jonkers, Sandra Heskamp, Carla M.L. van Herpen,Wim J.G. Oyen, Winette T.A. van der Graaf, and Otto C. Boerman. Theranostic applications of antibodies in oncology. Mol Oncol. 2014; 8(4): 799–812.
11. Hegdekar CN. Nanotechnology and the theranostic approach for the future management of cancer and the ethics of nanomedicine. 2010, medlink-uk.net.
12. Nimita L. Pharmacogenomics, Theranostics and Personalised medicine- The complexities of clinical trials: challenges in the developing world. Appl Transl Genomics, 2013; 2:17-21.
13. Santra S. The potential clinical impact of quantum dots. Nanomedicine (Lond). 2012; 7(5):623-626.
14. Feng Chen, Emily B. Ehlerding and Weibo Cai. Theranostic Nanoparticles. J Nucl Med. 2014 Dec; 55(12): 1919–1922.
15. Bhattarai N, Bhattarai SR. Therapeutic nanoparticles: A recent breakthrough in Nanotechnology. J Nanomed Nanotechnol. 2012; 3:e114.
16. Sairamesh J, Michael R. An economic perspective on personalized medicine. Hugo J. 2013; 7:1.

Published

2019-04-15

How to Cite

Shrivastava, S., Jain, S., Kumar, D., Soni, S. L., & Sharma, M. (2019). A Review on Theranostics: An Approach to Targeted Diagnosis and Therapy. Asian Journal of Pharmaceutical Research and Development, 7(2), 63–69. https://doi.org/10.22270/ajprd.v7i2.463

Most read articles by the same author(s)

1 2 3 > >>